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Abstract
Background: Infection with Salmonella enterica serovar Typhi (S. Typhi) with reduced susceptibility to fluoroquinolones has
been associated with fluoroquinolone treatment failure. We studied the relationship between ofloxacin treatment response
and the ofloxacin minimum inhibitory concentration (MIC) of the infecting isolate. Individual patient data from seven
randomised controlled trials of antimicrobial treatment in enteric fever conducted in Vietnam in which ofloxacin was used in
at least one of the treatment arms was studied. Data from 540 patients randomised to ofloxacin treatment was analysed to
identify an MIC of the infecting organism associated with treatment failure.
Principal Findings: The proportion of patients failing ofloxacin treatment was significantly higher in patients infected with
S. Typhi isolates with an MIC$0.25 mg/mL compared with those infections with an MIC of #0.125 mg/mL (p,0.001).
Treatment success was 96% when the ofloxacin MIC was #0.125 mg/mL, 73% when the MIC was between 0.25 and 0.50 mg/
mL and 53% when the MIC was 1.00 mg/mL. This was despite a longer duration of treatment at a higher dosage in patients
infected with isolates with an MIC$0.25 mg/mL compared with those infections with an MIC of #0.125 mg/mL.
Significance: There is a clear relationship between ofloxacin susceptibility and clinical outcome in ofloxacin treated patients
with enteric fever. An ofloxacin MIC of $0.25 mg/mL, or the presence of nalidixic acid resistance, can be used to define S.
Typhi infections in which the response to ofloxacin may be impaired.
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Introduction
Enteric fever is a systemic infection caused by Salmonella enterica
serovar Typhi (S. Typhi) and Salmonella enterica serovar Paratyphi A
(S. Paratyphi A) [1]. Antimicrobial therapy is critical for the
clinical management of enteric fever. The emergence and
sustained circulation of antimicrobial resistant organisms have
become problematic in many endemic regions [1,2]. Multiple drug
resistant S. Typhi (MDR: resistance to chloramphenicol, trimeth-
oprim/sulfamethoxazole and ampicillin) have been widespread
since the early 1990’s and hinder effective treatment and limit
alternatives.
Fluoroquinolones are commonly used for treating enteric fever
and have been recommended by the WHO for the treatment of
uncomplicated enteric fever caused by fully sensitive and MDR
organisms [3]. Ciprofloxacin and ofloxacin were chosen for
treating typhoid because of potent bactericidal activity against S.
Typhi and S. Paratyphi A, in vivo, both drugs have plasma levels
considerably in excess of the prevailing MICs and excellent
intracellular penetration [4]. Widespread use of fluoroquinolone
therapy for enteric fever has been followed by the emergence of S.
Typhi and S. Paratyphi A isolates with elevated minimum
inhibitory concentrations (MIC) to ciprofloxacin and ofloxacin
across Asia and in parts of Africa [5,6,7,8,9]. These strains are
associated with point mutations in the gyrA gene and occasionally
the parC gene [5,7,9,10,11,12]. To date, there have been few
published reports of plasmid mediated quinolone resistance
(PMQR) genes, such as qnr, aac(69)-Ib-cr, or efflux pumps, in S.
Typhi as described in some non-typhoidal Salmonella serovars
[2,13]. The identification of strains with reduced susceptibility to
fluoroquinolones is important to guide treatment, yet these strains
are categorised as susceptible by the current guidelines for
fluoroquinolone disk susceptibility testing [14,15,16]. Such isolates
can be identified by using resistance to nalidixic acid as a surrogate
marker of fluoroquinolone susceptibility, although this is not
completely reliable [17,18]. Enteric fever caused by S. Typhi
strains with an elevated MIC to ciprofloxacin and ofloxacin have
been coupled with the failure of treatment with these antimicro-
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bials and increased disease severity [12,19,20,21,22]. Yet, a clear
correlation between the MIC of the infecting organism to
fluoroquinolones and the clinical response to fluoroquinolone
therapy has not been defined. The aim of this work was to study
the relationship between the response to ofloxacin treatment and
the ofloxacin MIC of the infecting isolate and define an MIC
breakpoint that can predict a poor therapeutic response to
ofloxacin. We have analysed individual patient data combined
from seven open randomised controlled trials (RCTs) using a
standard protocol that had been conducted in Vietnam of
uncomplicated enteric fever caused by S. Typhi.
Methods
Ethics statement
The study was conducted according to the principles expressed
in the Declaration of Helsinki and approved by the Institutional
Review Board of the Hospital for Tropical Diseases and the
additional hospital involved in the studies. All patients provided
verbal informed consent (verbal informed consent was provided by
the parents or guardian of children under 18 years of age) for the
collection of samples and subsequent analysis.
Study setting
We analysed the results of seven open RCTs for enteric fever
conducted in southern Vietnam between 1992 and 2001 in
which treatment with ofloxacin was used in at least one of the
trial arms. All the RCTs were conducted using a standard
protocol, except for the dose and duration of ofloxacin
treatment and the alternative treatment regimens used. The
RCTs were conducted at three study sites in southern Vietnam:
The Hospital for Tropical Diseases, Ho Chi Minh City
[23,24,25,26]; Dong Thap Provincial Hospital, Cao Lanh,
Dong Thap Province [27,28] and Dong Nai Provincial Hospital,
Bien Hoa, Dong Nai Province [29]. All studies were approved
by the Ethical Committee of the Hospital conducting the study.
The studies were conducted in accordance with ICH and
Declaration of Helsinki guidelines.
Clinical procedures
Patients with suspected uncomplicated enteric fever were
allocated to one of each of the treatment groups in an open
randomised comparison. A computer generated randomisation list
was produced by a member of staff that was not otherwise
involved in the study. The treatment allocations were kept in
serially numbered sealed opaque envelopes that were only opened
after the patient had been enrolled into the study. The treatment
arms were ofloxacin (Oflocet, Hoescht Marion Roussel, Paris,
France) at a dose that varied between 10 and 20 mg/kg/day orally
in two-divided dose (maximum 400 mg twice daily) for between
two and seven days (depending on the study, or the comparator).
The comparator arms were, either, a different regimen of
ofloxacin (in three RCTs) [24,26,28] ceftriaxone [25], cefixime
[29], or azithromycin (in two RCTs) [23,27].
Patients were excluded if; they refused consent, had evidence of
progressive or complicated disease, had inability to swallow oral
medication, had a history of significant underlying disease, had
hypersensitivity to either of the trial drugs or were pregnant or
lactating. Additionally, patients who gave a history of treatment with
a fluoroquinolone, a third generation cephalosporin or a macrolide
within one week of hospital admission were also excluded.
Clinical definitions
In all seven studies, patients were examined daily until discharge
from hospital, with particular reference to clinical symptoms and
complications of the disease and body temperature was measured
every six hours. Response to treatment was assessed by the
resolution of clinical symptoms and signs, the fever clearance time
(time from the start of treatment until the body temperature
reached #38.0uC, and remained #38.0uC for 48 hours), the
development of complications or death, any evidence of relapse of
infection and persistent fecal carriage after the conclusion of
treatment or at the one month follow up visit.
Clinical treatment failure was defined as the persistence of fever
(.38uC) and other enteric fever related symptoms for more than
seven days after the initiation of treatment or the development of
severe complications (severe gastrointestinal bleeding, intestinal
perforation, visible jaundice, myocarditis, pneumonia, renal
failure, shock or an altered conscious level) during treatment
which required a change in therapy. Microbiological treatment
failure was defined as isolation of S. Typhi from blood or a sterile
site after the completion of treatment. Post study fecal carriage was
defined as a positive fecal culture, with an isolate having the same
susceptibility pattern as the original isolate, after the end of the
initial treatment and before hospital discharge.
Patients were requested to return for a follow up assessment at
four weeks or earlier if their symptoms recurred. Clinical evidence
of relapse was sought and one fecal culture was performed. A
blood culture was performed if the symptoms and signs suggested
relapse. A relapse was defined as a recurrence of symptoms and
signs suggestive of enteric fever within the four week period after
the patient had been discharged well from the hospital
accompanied by a blood culture positive for S. Typhi. One month
faecal carriage was defined as a positive faecal culture at the one
month follow up visit, with an isolate having the same
susceptibility pattern as the original isolate.
Laboratory investigations and microbiology
A hematocrit, white cell, platelet count and blood differential
count were performed with serum aspartate transaminase, alanine
transaminase, creatinine levels and urinalysis before therapy was
initiated. Aspartate transaminase and alanine transaminase
measurements were repeated one day after the end of therapy.
Author Summary
Typhoid fever is an infection of the bloodstream caused by
the organism Salmonella Typhi (S. Typhi). Treatment with
antimicrobials is critical for preventing severe infection and
even death, yet antimicrobial resistant organisms have
become a problem in many places where typhoid is
common. Fluoroquinolones are a group of antimicrobials
that are commonly used to treat typhoid, we analysed
data from 540 enteric fever patients treated with ofloxacin
(a fluoroquinolone) to identify a level of resistance
(minimum inhibitory concentration (MIC)) from the infect-
ing organism which is associated with treatment failure.
The proportion of patients failing treatment was higher in
those infected with a bacterium with an MIC$0.25 mg/mL,
compared with those infections with an MIC of #0.125 mg/
mL. Treatment success was 96% when the ofloxacin MIC
was #0.125 mg/mL, yet only 53% when the MIC was
1.00 mg/mL. Our data demonstrates that an S. Typhi
bacterium with an ofloxacin MIC of $0.25 mg/mL corre-
lates with a poor outcome when treated with this
antimicrobial. Therefore, we propose an amendment in
the current MIC guidelines for microbiology laboratories to
aid clinicians treating typhoid and suggest the use of
alternative therapy in these patients.
Response to Ofloxacin in Typhoid Fever
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A full blood count was repeated if there was a suggestion of
gastrointestinal bleeding or clinical evidence of anaemia. Blood
and fecal cultures were obtained before therapy and in one study a
bone marrow was also performed in selected patients [27]. A blood
culture was performed on all patients a day after the end of
treatment. In addition, three fecal specimens were cultured
between two and four days after the end of treatment and at the
one month follow up visit. Bacterial culturing was performed as
previously described [23,24,25,26,27,28,29], colonies presumptive
of S. Typhi were identified using standard biochemical tests and
serotype-specific antisera (Murex Biotech, Dartford, England).
Antimicrobial sensitivities were performed by the modified
Bauer-Kirby disc diffusion method with zone size interpretation
based on CLSI guidelines [30]. Antimicrobial discs tested were
chloramphenicol (30 mg), ampicillin (10 mg), trimethoprim -
sulphamethoxazole (1.25/23.7 5 mg), ceftriaxone (30 mg), ofloxacin
(5 mg), azithromycin (15 mg) and nalidixic acid (30 mg). Isolates
were stored in protect beads (Prolabs, Oxford, United Kingdom)
at 220uC for later ofloxacin MIC testing by agar plate dilution
[31]. Escherichia coli ATCC25922 and Staphylococcus aureus
ATCC25923 were used as control strains for these assays. An
isolate was defined as MDR if it was resistant to chloramphenicol
($32 mg/ml), ampicillin ($32 mg/ml) and trimethoprim/sulfa-
methoxazole ($8/152 mg/ml). An isolate was defined as nalidixic
acid resistant if it had an MIC of $32 mg/ml [15].
Statistical analysis
Analysis was restricted to patients in whom S. Typhi was
isolated from blood or bone marrow culture prior to treatment
with ofloxacin and in whom the ofloxacin MIC of the original
infecting isolate had been determined. The pooled admission and
outcome data for individual patients was compiled with respect to
the ofloxacin MIC of the original infecting isolate. Proportions
were compared with the Chi squared test, Fisher’s exact test or
analysis of variance. Normally distributed data were compared
using the Student t-test, non-normally distributed data using the
Mann Whitney U test or Kruskall Wallis test. The fever clearance
time was compared using survival analysis and the log rank test.
Independent risk factors for clinical failure in the clinical trials
were determined by multivariate logistic regression, a p value of
,0.05 was considered significant. Statistical analysis was per-
formed using SPSS for Windows version 18 (SPSS Inc, Chicago,
USA).
Results
Clinical features of enteric fever patients treated with
ofloxacin
A total of 540 patients infected with S. Typhi, treated with
ofloxacin and in whom the ofloxacin MIC of the isolate was
known from seven RCTs were available for analysis. The
distribution of ofloxacin MIC values across the different trials is
shown in Figure 1. The clinical features of the patients at the time
of admission in relation to the ofloxacin MIC of the infecting S.
Typhi isolate are shown in Table 1. There was heterogeneity
among the six MIC (to ofloxacin) groups (#.032 mg/ml,
0.064 mg/ml, 0.125 mg/ml, 0.25 mg/ml, 0.50 mg/ml and 1 mg/
ml) with respect to a number of features, including the number of
Figure 1. The distribution of S. Typhi MIC to ofloxacin in seven RCTs. Histogram showing the distribution of S. Typhi MICs (,0.06, 0.06,
0.125, 0.25, 0.5 and 1 mg/mL) to ofloxacin over seven individual randomised. The proportion of S. Typhi strains with the corresponding MIC are
shaded accordingly, white; study TY1 (1992–1993) n = 19 [25], very light grey; study CT1 (1993–1994) n = 102 [26], light grey; study TY2 (1993–1996)
n = 103 [24], mid grey; study DTC (1994–1995) n = 154 [28], dark grey; study DN (1995–1996) n = 55 [29], very dark grey; study TY3 (1997–1998) n = 45
[23] and black; study DTY2 (1998–2001) n = 62 [27].
doi:10.1371/journal.pntd.0001163.g001
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patients in each group. Abdominal pain, vomiting and positive
fecal cultures were more frequently observed in patients infected
with an isolate with a higher ofloxacin MIC. Nalidixic acid
resistance was observed in none of the 423 S. Typhi isolates with
an ofloxacin MIC of #0.06 mg/mL, in 2/12 (17%) of isolates with
an MIC of 0.125 mg/mL and 104/105 (99%) of those with an
MIC$0.25 mg/mL (p,0.001) (Table 1).
Clinical response of enteric fever patients to ofloxacin
therapy
Details of the duration and dosage of ofloxacin treatment and
the corresponding response to therapy are shown in Table 2. The
median duration of therapy for patients infected with S. Typhi
isolates with an MIC,0.125 mg/mL was three days at a median
dose of 11 mg/kg. In patients infected with S. Typhi isolates with
an MIC of between 0.125–0.25 mg/mL the median duration of
therapy was three days at a median dose of 13–15 mg/kg. For
patients infected with isolates with an MIC.0.25 mg/mL the
median duration of therapy was seven days at a dose of 16–
18 mg/kg.
We calculated the ratio of the administered dose of ofloxacin
(mg/kg) to the MICs of the infecting isolates. The ratio of
administered dose to bacterial MIC declined from 370 in patients
infected with an S. Typhi isolate with an MIC of #0.03 mg/mL to
18 in those infected with an S. Typhi isolate with an MIC of
1.0 mg/mL. Despite a longer duration of treatment at a higher
dosage, the proportion of patients failing treatment was signifi-
cantly higher in the patients infected with S. Typhi isolates with an
MIC$0.25 mg/mL compared with those infected with isolates
with an MIC of #0.125 mg/mL (p,0.001). Concurrently, the time
to fever clearance was significantly longer in the patients with a
higher MIC (Figure 2 and Table 2). There was an evident
relationship between fever clearance time and the MIC of the
infecting organism, as shown in Figure 3. Furthermore, the
proportion of patients with a positive faecal culture, immediately
post study treatment and at one month follow-up was also
significantly greater among the patients infected with an isolate
with a higher MIC to ofloxacin, p,0.001 and p = 0.001
respectively (Table 2).
Of the 540 patients, 15 (2.8%) developed a potentially life
threatening complication during the course of treatment (gastro-
intestinal bleed requiring transfusion, hemodynamic shock,
suspected myocarditis, encephalopathy, pneumonia) and one
patient died of suspected myocarditis and shock. There was no
significant difference in the rate of life-threatening complications
for the patients infected with isolates with different ofloxacin MICs
(Table 2).
Predicting clinical failure to ofloxacin therapy in enteric
fever patients
Univariate analysis was performed to identify the factors that
were associated with clinical failure. The presence of abdominal
pain (p,0.001), diarrhoea (p = 0.03), vomiting (p,0.001), lower
hematocrit (p = 0.03), lower white cell count (p = 0.04), lower
platelet count (p = 0.002), infection with an S. Typhi organism with
a higher ofloxacin MIC (p,0.001), prolonged duration of
ofloxacin treatment (p,0.001) and a higher administered dose of
ofloxacin (p = 0.009) were all associated with clinical failure.
Duration of therapy was deliberately increased as the MIC
increased. If this factor is not included in the model, the
independent variables associated with clinical failure with
ofloxacin treatment using a multivariate logistic regression model
were, abdominal pain, Odds Ratio (OR) 0.461, 95% confidence
Interval (95% CI) 0.233–0.969, p = 0.033, vomiting; OR 0.427,
95% CI; 0.208–0.876, p = 0.020, hematocrit; OR 0.924, 95% CI;
0.861–0.992, p = 0.033, platelet count; OR 0.990, 95% CI; 0.984–
1.00, p = 0.001) and the ofloxacin MIC of the infecting isolate; OR
17.08, 95% CI; 6.62–44.04, p,0.001.
To define an appropriate ofloxacin MIC breakpoint and the use
of nalidixic acid resistance to define clinical failure to ofloxacin, the
clinical success rate in each MIC group was calculated (Table 3).
The data stratified by MIC to ofloxacin suggests a treatment
Table 1. Admission features of 540 ofloxacin treated enteric fever patients recruited to clinical trials.
Admission featuresa Ofloxacin MIC (mg/mL) of infecting isolate of S. Typhi pb
#.032 0.064 0.125 0.25 0.50 1.0
Number 152 271 12 20 47 38
Duration of illness (days) 8 (7–12) 7 (6–10) 9 (6–11) 10 (7–12) 8 (6–14) 7 (4–10) 0.079
Abdominal pain [n (%)] 36 (24) 97 (36) 4 (33) 7 (35) 23 (49) 29 (76) ,0.001
Diarrhoea [n (%)] 86 (57) 175 (65) 10 (83) 12 (60) 38 (81) 31 (82) 0.005
Vomiting [n (%)] 26 (17) 51 (19) 1 (8) 4 (20) 12 (26) 20 (53) ,0.001
Hepatomegaly [n (%)] 76 (50) 195 (72) 8 (67) 12 (60) 27 (57) 24 (63) 0.001
Splenomegaly [n (%)] 22 (15) 44 (16) 2 (17) 6 (30) 2 (4) 3 (8) 0.081
Haematocrit (%) 35 (33–38) 34 (30–38) 32 (30–36) 36 (32-4) 34 (32–38) 35 (31–38) 0.042
White cell count 7.4 (5.7–9.2) 7.3 (5.8–9.2) 6.3 (5.3–8.4) 5.9 (5.0–9.0) 7.0 (5.4–9.5) 6.5 (5.3–8.2) 0.441
Platelet count 172 (152–203) 164 (140–200) 168 (156–243) 164 (149–185) 166 (128–227) 174 (123–225) 0.881
Fecal culture positive [n (%)] 16/132 (12) 23/239 (10) 1/9 (10) 4/11 (27) 13/40 (33) 8/32 (25) 0.001
Isolate MDRc [n (%)] 121 (80) 218 (80) 10 (83) 19 (95) 45 (96) 45 (96) 0.248
Isolate NaRd [n (%)] 0 (0) 0 (0) 2 (17) 20 (100) 46 (98) 38 (100) ,0.001
a) continuous variables given as median (interquartile range), and proportions as number (%).
b) Analysis of variance for proportions, Kruskall Wallis test for continuous variables.
c) MDR – resistant to ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole.
d) NaR – resistant to nalidixic acid.
doi:10.1371/journal.pntd.0001163.t001
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Table 2. Treatment response of 540 ofloxacin treated enteric fever patients recruited to clinical trials.
Treatment and outcomea Ofloxacin MIC (mg/mL) of infecting isolate of S.Typhi P b
#.032 0.064 0.125 0.25 0.50 1.0
Number of patients 152 271 12 20 47 38
Treatment duration (days) 3 (2–3) 3 (2–3) 3 (3–5) 3 (2–3) 7 (5–7) 7 (7-7) ,0.001
Mean ofloxacin dose/kg 11 (9–14) 11 (10–13) 13 (9–15) 15 (9–15) 16 (9–20) 18 (14–20) ,0.001
Mean ofloxacin dose/MIC 370 (317–489) 175 (167–222) 102 (75–120) 60 (36–60) 32 (17–40) 18 (14–20) ,0.001
Clinical failure [n (%)] 4 (3) 13 (5) 1 (8) 5 (25) 13 (28) 18 (47) ,0.001
Microbiological failure [n(%)] 1 (1) 2 (1) 0 (0) 1 (5) 1 (2) 2 (5) 0.499
Fever clearance time (days) 3.1 (2.5–4.2) 3.8 (2.8–4.8) 4.8 (3.1–7.4) 6.0 (3.5–10.3) 7.3 (5.3–9.8) 8.4 (6.8–11.3) ,0.001
Life-threatening complication n[%] 5 (3.3) 9 (3.3) 0 (0) 0 (0) 1 (2.1) 0 (0) 0.198
Post study feces positive [n (%)] 1/120 (1) 4/229 (2) 2/11 (18) 1/17 (6) 11/43 (26) 7/37 (20) ,0.001
1 month feces positive [n (%)] 0/61 (0) 0/83 (0) 1/4 (25) 1/19 (11) 3/29 (10) 1/29 (3) 0.001
Relapse [n (%)] 2/61 (3) 4/87 (5) 0/4 (0) 1/11 (9) 1/35 (3) 0/32 (0) ,0.001
a) continuous variables given as medians (interquartile range), and proportions as numbers (%).
b) Analysis of variance for proportions, Kruskall Wallis test for continuous variables and Log rank test for fever clearance time.
doi:10.1371/journal.pntd.0001163.t002
Figure 2. The relationship between increasing S. Typhi MIC to ofloxacin and clinical failure. Histogram showing the proportion of enteric
fever patients who failed treatment (white columns) or had persistent fever (black columns) (.38uC) for more than seven days after the
commencement of treatment. Data was combined from seven randomised clinical trials and is comprised from 540 children and adults recruited with
uncomplicated enteric fever. The patients are divided according to the MIC to ofloxacin of the infecting isolate.
doi:10.1371/journal.pntd.0001163.g002
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success rate with ofloxacin given for a median duration of 3 days at
11–13 mg/kg of 96% in 435 patients infected with an isolate with
an ofloxacin MIC of #0.125 mg/mL; 73% in 67 patients infected
with isolate with an ofloxacin MIC between 0.25 and 0.5 mg/mL
with treatment durations between 3 to 7 days at 15–16 mg/kg;
and 53% in 38 patients infected with an isolate with an ofloxacin
MIC of 1.00 mg/mL despite a median duration of treatment of 7
days at 18 mg/kg. The success rate in 434 patients infected with a
nalidixic acid susceptible isolate was 96% compared with a 65%
success rate in the 106 patients infected with a nalidixic acid
resistant isolate.
Discussion
In this study we used individual patient data from seven
randomised controlled trials to characterise the relationship
between ofloxacin susceptibility and outcome in ofloxacin treated
patients with uncomplicated enteric fever. There was clear
relationship between a higher ofloxacin MIC of the infecting
isolate and a declining response to ofloxacin. Although the trials
were conducted according to a standard protocol, the duration
and dosage of ofloxacin treatment was not standard across all
patient groups and the duration for some patients was shorter than
would be routinely recommended. Despite this, a successful
response in 96% of patients to an average duration of treatment of
three days among infections with an ofloxacin MIC,0.25 mg/mL
indicates the efficacy of ofloxacin when isolates are fully susceptible
and justifies comparison with the response to infections where the
isolate had a higher MIC and the ofloxacin dose used was higher
and duration longer.
Our data suggests an MIC breakpoint for ofloxacin of
$0.25 mg/mL or the presence of nalidixic acid resistance could
be used to define infections in which the response to ofloxacin is
impaired. The ciprofloxacin MIC is usually one dilution less than
ofloxacin, and this implies a ciprofloxacin breakpoint of
$0.125 mg/mL, a breakpoint already suggested [32,33]. The
small number of infections with isolates with an MIC of 0.125 mg/
mL is a limitation and more information on the response to
treatment at this MIC would be valuable. As nalidixic acid
resistance is not a reliable proxy marker for reduced fluoroquin-
Figure 3. The duration of febrile episodes in enteric fever patients infected with S. Typhi organisms with a range of MICs to
ofloxacin. Kaplan Meir curve showing the proportion of patients remaining febrile (.38uC) after the start of treatment with ofloxacin. Data is
composed from fever clearance times of 540 children and adults with uncomplicated enteric fever recruited to seven randomised clinical trial and
treated with oral ofloxacin. The curves are divided according to the ofloxacin MIC of the infecting isolates and are highlighted on the diagram.
doi:10.1371/journal.pntd.0001163.g003
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olone susceptibility in S. Typhi [17] we endorse the re-evaluation
of disk susceptibility breakpoints for fluoroquinolones against S.
Typhi by the clinical and laboratory standards institute (CSLI)
[34]. This study only includes infections with S. Typhi so we can
only propose applying similar breakpoints for S. Paratyphi A.
Antimicrobial resistant S. Paratyphi A is an emerging problem in
Asia and similar clinical characterisation of S. Paratyphi A
infections is required [35].
A number of previous studies have reported an impaired
response in typhoid fever to ciprofloxacin or ofloxacin when the
isolates have decreased susceptibility. In general these studies are
case reports or case series, mostly retrospective, or small numbers
of patients in clinical trials. Despite these reports there has been a
reluctance to change the MIC and disc susceptibility breakpoints
for ciprofloxacin and ofloxacin and Salmonella. The data presented
in this study were collected prospectively in the context of
randomised controlled trials with uniform methods of collecting
the treatment outcomes, during a period when the proportion of S.
Typhi strains with reduced susceptibility to ciprofloxacin and
ofloxacin changed from negligible to the majority. Reduced
susceptibility to fluoroquinolones in the strains isolated during the
period when these studies were conducted were predominantly
associated with point mutations in gyrA and were typical of strains
from other locations at this time [5]. This is a unique set of data
that is unlikely to be repeated, with sufficient numbers of cases to
provide a clear and definitive demonstration that an elevated MIC
to ofloxacin is associated with treatment failure. We feel that the
data are sufficiently convincing that it should now lead to a change
in the MIC and disc susceptibility breakpoints for S. Typhi with
ofloxacin and, potentially, ciprofloxacin.
Pharmacokinetic and pharmacodynamic (PK-PD) parameters
are likely to be an important factor in the response to
fluoroquinolone therapy. A study using an in vitro model of S.
Typhi infection and Monte Carlo simulations to explore PK-PD
parameters that were predictive of efficacy found that the free drug
area under the concentration-time curve from 0 to 24 h/MIC
ratio (AUC/MIC ratio) was the parameter most predictive of
efficacy and that a ratio of 105 corresponded to 90% of maximal
activity [36]. The pharmacokinetics of ofloxacin was not measured
in the trials studied here. However, using the dose/kg of ofloxacin
given as a crude measure of drug exposure, the data in this analysis
suggests that when the ratio of the mean ofloxacin dose/kg divided
by the MIC of the infecting organism is above 100 the treatment
response is satisfactory, but when it is below 100 the treatment
response is impaired. It should be noted that the plasma
concentration of fluoroquinolone in individual patients given the
same dose is variable. This, as well as other factors such as age and
immune status, may explain why not all patients that have an
organism with an MIC$0.25 mg/mL will fail therapy. We suggest
that future trials in enteric fever should include pharmacokinetic
measurements to allow proper analysis of PK-PD parameters.
Some studies have suggested a higher rate of life-threatening
complications in patients infected with S. Typhi isolates with
decreased susceptibility to fluoroquinolones [22]. In this study
there were no significant differences in the rate of life-threatening
complications between the patients infected with isolates with
different MICs. The rate of patients with life-threatening
complications (2.2%) was lower than would be the case in
unselected patients, as the subjects selected for these trials were
specifically screened for uncomplicated disease at enrolment.
Conclusions
S. Typhi strains that exhibit MICs to ofloxacin that are higher
than those observed in this study are emerging and the ongoing
use of fluoroquinolones, such as, ofloxacin and ciprofloxacin, to
treat S. Typhi infections with reduced susceptibility may be
driving their selection [13,37,38]. The increased fecal carriage
following ofloxacin treatment of isolates with reduced ofloxacin
susceptibility is also likely to drive increased local transmission.
We suggest azithromycin, a third generation cephalosporin, or a
later generation fluoroquinolone to be considered as alternatives
for MDR S. Typhi isolates with an ofloxacin MIC of $0.25 mg/
mL [20,27,39,40]. Yet, there is an obvious risk of emerging
resistance to these alternative antimicrobial agents [41] and
dosing regimens need careful design to prevent this. Our data
demonstrates that an S. Typhi isolate with an ofloxacin MIC of
$0.25 mg/mL correlates with a poor clinical outcome when
treated with this antimicrobial and we propose an amendment in
the S. Typhi susceptibility breakpoints for ofloxacin and
ciprofloxacin [34].
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